IUGRIUGR-Fetuin-BNCT07869004
Intrauterine Fetal Growth Restriction and Fetuin-B
An observational study of IUGR, run by Karadeniz Technical University at 1 site in Turkey (Türkiye).
Trial summary
Brief Summary This study aims to evaluate the relationship between fetuin-B levels and intrauterine growth restriction (IUGR). Maternal serum fetuin-B levels will be compared between pregnant women with IUGR and those with appropriate fetal growth. Read more about this study
- Who is it for?
- Ages 18 to 45 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- IUGR
- What is being tested?
- measure fetuin b
- How many people
- 30 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 30 Oct 2026to 28 Feb 2027
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: The study population will consist of pregnant women with singleton pregnancies who are evaluated during pregnancy at the participating center. The study group will include pregnant women diagnosed with intrauterine growth restriction (IUGR) according to predefined fetal growth and Doppler criteria. The control group will consist of pregnant women with appropriate-for-gestational-age (AGA) fetuses without evidence of IUGR. Maternal serum samples will be collected from participants to measure fetuin-B levels, and clinical, obstetric, fetal biometric, and Doppler parameters will be evaluated.
Who may be able to join
- Pregnant women with a singleton pregnancy.
- Gestational age between [X and Y] weeks at the time of enrollment.
- Pregnant women diagnosed with intrauterine growth restriction (IUGR) according to predefined fetal growth and Doppler criteria for the study group.
- Pregnant women with an appropriate-for-gestational-age (AGA) fetus for the control group.
- Availability of maternal serum samples for fetuin-B measurement.
- Provision of written informed consent to participate in the study.
Who cannot join
- Multiple pregnancy.
- Major fetal congenital or chromosomal anomalies.
- Known maternal chronic diseases that may significantly affect fetal growth or fetuin-B levels, such as pre-existing diabetes mellitus, chronic hypertension, renal disease, or autoimmune disease.
- Maternal infection or other conditions associated with fetal growth restriction, when clinically relevant.
- Placental abnormalities that may independently affect fetal growth.
- Pregnancies with incomplete clinical, laboratory, ultrasonographic, or Doppler data.
- Inability or unwillingness to provide informed consent.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site
Karadeniz technical university, school of medicine
Akçaabat, Trabzon, (530) 548 04 97
About this study
Official title: Evaluation of the Relationship of IUGR Patients With Fetun-B
Brief Summary
This study aims to evaluate the relationship between fetuin-B levels and intrauterine growth restriction (IUGR). Maternal serum fetuin-B levels will be compared between pregnant women with IUGR and those with appropriate fetal growth. The study will also assess whether fetuin-B levels are associated with clinical and obstetric characteristics, fetal growth parameters, and Doppler findings. The findings may provide further insight into the potential role of fetuin-B in the pathophysiology and clinical assessment of IUGR.
- Conditions
- IUGR
- Being tested
- measure fetuin b
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
measure fetuin bOther
No intervention is administered. This is an observational study in which maternal serum fetuin-B levels are measured and compared between pregnant women with intrauterine growth restriction (IUGR) and pregnant women with appropriate-for-gestational-age (AGA) fetuses.
| Study group | Role | What they receive |
|---|---|---|
| IUGR Group | Pregnant women diagnosed with intrauterine growth restriction (IUGR) according to established clinical and ultrasonographic criteria. Maternal serum fetuin-B levels, fetal growth parameters, and Doppler findings will be evaluated. Receives: Other: measure fetuin b | |
| Control Group (AGA) | Pregnant women with appropriate-for-gestational-age (AGA) fetuses and without evidence of intrauterine growth restriction. Maternal serum fetuin-B levels, fetal growth parameters, and Doppler findings will be evaluated. Receives: Other: measure fetuin b |
What is being measured
The primary outcome is the main question the study is designed to answer.
Maternal Serum Fetuin-B Level
Maternal serum fetuin-B levels will be measured and compared between pregnant women with intrauterine growth restriction (IUGR) and pregnant women with appropriate-for-gestational-age (AGA) fetuses to evaluate the association between fetuin-B levels and IUGR.
Measured: At the time of diagnosis of IUGR or at the corresponding gestational age in the control group. It is time between the 24th and 37th weeks of pregnancy.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Oct 2026
- Study start30 Oct 2026 (estimated)
- Primary completion30 Jan 2027 (estimated)
- Study completion28 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for IUGRStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 30 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Karadeniz Technical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, hidayet şal, Karadeniz Technical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07869004
- Sponsor's protocol ID
- 2026-310
- Acronym
- IUGR-Fetuin-B
- Status last verified
- Oct 2026
- First submitted
- 30 Sep 2026
- Last updated
- 9 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: No. Individual participant-level data will not be made available to other researchers.
Study at a glance
From the registry record, last updated by the sponsor on 9 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Relationship of IUGR Patients With Fetun-B
- ClinicalTrials.gov ID
- NCT07869004
- Acronym / sponsor ID
- IUGR-Fetuin-B / 2026-310
- Conditions
- IUGR
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Karadeniz Technical UniversityUniversity, hospital or other
- Study start
- 30 Oct 2026 (estimated)
- Primary completion
- 30 Jan 2027 (estimated)
- Study completion
- 28 Feb 2027 (estimated)
- First posted
- 9 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Brief Summary
This study aims to evaluate the relationship between fetuin-B levels and intrauterine growth restriction (IUGR). Maternal serum fetuin-B levels will be compared between pregnant women with IUGR and those with appropriate fetal growth. The study will also assess whether fetuin-B levels are associated with clinical and obstetric characteristics, fetal growth parameters, and Doppler findings. The findings may provide further insight into the potential role of fetuin-B in the pathophysiology and clinical assessment of IUGR.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Target follow-up
- 1 Year
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| IUGR Group | – | Other: measure fetuin bPregnant women diagnosed with intrauterine growth restriction (IUGR) according to established clinical and ultrasonographic criteria. Maternal serum fetuin-B levels, fetal growth parameters, and Doppler findings will be evaluated. |
| Control Group (AGA) | – | Other: measure fetuin bPregnant women with appropriate-for-gestational-age (AGA) fetuses and without evidence of intrauterine growth restriction. Maternal serum fetuin-B levels, fetal growth parameters, and Doppler findings will be evaluated. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- The study population will consist of pregnant women with singleton pregnancies who are evaluated during pregnancy at the participating center. The study group will include pregnant women diagnosed with intrauterine growth restriction (IUGR) according to predefined fetal growth and Doppler criteria. The control group will consist of pregnant women with appropriate-for-gestational-age (AGA) fetuses without evidence of IUGR. Maternal serum samples will be collected from participants to measure fetuin-B levels, and clinical, obstetric, fetal biometric, and Doppler parameters will be evaluated.
Key inclusion criteria (6 listed)
- Pregnant women with a singleton pregnancy.
- Gestational age between [X and Y] weeks at the time of enrollment.
- Pregnant women diagnosed with intrauterine growth restriction (IUGR) according to predefined fetal growth and Doppler criteria for the study group.
- Pregnant women with an appropriate-for-gestational-age (AGA) fetus for the control group.
- Availability of maternal serum samples for fetuin-B measurement.
Key exclusion criteria (7 listed)
- Multiple pregnancy.
- Major fetal congenital or chromosomal anomalies.
- Known maternal chronic diseases that may significantly affect fetal growth or fetuin-B levels, such as pre-existing diabetes mellitus, chronic hypertension, renal disease, or autoimmune disease.
- Maternal infection or other conditions associated with fetal growth restriction, when clinically relevant.
- Placental abnormalities that may independently affect fetal growth.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| measure fetuin bNo intervention is administered. This is an observational study in which maternal serum fetuin-B levels are measured and compared between pregnant women with intrauterine growth restriction (IUGR) and pregnant women with appropriate-for-gestational-age (AGA) fetuses. | Other | Control Group (AGA), IUGR Group |
Primary outcome
Maternal Serum Fetuin-B Level
Time frame: At the time of diagnosis of IUGR or at the corresponding gestational age in the control group. It is time between the 24th and 37th weeks of pregnancy.
Maternal serum fetuin-B levels will be measured and compared between pregnant women with intrauterine growth restriction (IUGR) and pregnant women with appropriate-for-gestational-age (AGA) fetuses to evaluate the association between fetuin-B levels and IUGR.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Oct 2026.
- Individual participant dataSharing planned: No. No. Individual participant-level data will not be made available to other researchers.
Related trials for IUGR
RecruitingObservational study
Growing Little PEAPODS Study
Premature Birth, Premature Infant
Recruiting
STV Analysis Versus Visual Evaluation of Cardiotocography in FGR
Fetal Growth Retardation
RecruitingPhase 2
Statin Intervention for Severe Early-Onset Placental Insufficiency. (STATIN-PRE Trial)
Preeclampsia (PE), Intrauterine Growth Restriction (IUGR)
RecruitingObservational study
Natural History of Craniofacial Anomalies and Developmental Growth Variants
Prognathism, Retrognathism
RecruitingObservational study
Primordial Dwarfism Registry
MOPDII, Meier-Gorlin Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of IUGR, run by Karadeniz Technical University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 9 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Maternal Serum Fetuin-B Level (time frame: At the time of diagnosis of IUGR or at the corresponding gestational age in the control group. It is time between the 24th and 37th weeks of pregnancy.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2026.